Motus GI to Present at the Ladenburg Thalmann 2018 Healthcare Conference
FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--Oct 1, 2018--Motus GI Holdings, Inc., (NASDAQ: MOTS) (“Motus GI” or the “Company”), a medical technology company dedicated to improving clinical outcomes and enhancing the cost-efficiency of colonoscopy, announced today that Mark Pomeranz, President and COO of Motus GI, will present at the Ladenburg Thalmann 2018 Healthcare Conference on Tuesday, October 2, 2018 at 3:00 p.m. EDT in New York, NY.
As part of his presentation, Mr. Pomeranz will provide a corporate overview, along with an update on the current pre-launch, market development activities and ongoing REDUCE clinical study of the Company’s flagship product, the Pure-Vu® System. The Pure-Vu® System is designed to rapidly cleanse the colon during a colonoscopy, potentially removing the dependency on difficult and lengthy pre-procedural preparations and may allow physicians to better visualize, diagnose and, if necessary, treat the colon using standard techniques and tools. This capability is important for inpatients that may have emergent issues like a lower GI bleed who may benefit from accelerated diagnosis. Since most of inpatient colonoscopies are currently covered under the bundled payment of a Diagnosis-Related Group (“DRG”) reimbursement, Motus GI believes such accelerated diagnosis has the potential to enhance hospital efficiency by improving quality of care, reducing direct costs and the length of stay, as well as accelerating bed turn-over for new patients. Challenges with bowel preparation for inpatient colonoscopy represent a significant area of unmet need that directly affects clinical outcomes and increases the cost of care in a market segment that comprises approximately 1.5 million annual procedures in the U.S. and approximately 4 million annual procedures worldwide.
The Pure-Vu® System fits on commercially available standard and slim colonoscopes and generates a proprietary pulsed vortex™ mixture of water and air to safely remove debris while simultaneously evacuating the bowel contents, allowing the endoscopist to perform a quality examination even when the patient does not or is not able to complete a successful prep on his or her own. Motus GI’s clinical trials, such as the ongoing REDUCE study and its upcoming EXPEDITE study, are designed to evaluate the Pure-Vu System’s ability to address delays and inefficiencies in the inpatient population. The Pure-Vu® System and Pure-Vu® Slim have received 510(k) clearance from the U.S. Food and Drug Administration and The Pure-Vu® System has received CE mark approval in Europe, and is currently being introduced on a pilot basis in the US.
In addition to the presentation, Mr. Pomeranz and the Company’s new CEO, Tim Moran, will be available to participate in one-on-one meetings with qualified members of the investor community who are registered to attend the conference.
A live audio webcast of the presentation will be accessible on the Events page of the Investors section on the Company’s website at www.motusgi.com. The webcast replay will be available approximately two hours after the presentation ends and will be accessible for 90 days.
About Motus GI and the Pure-Vu® System
Motus GI Holdings, Inc. is a medical technology company, with subsidiaries in the U.S. and Israel, dedicated to improving clinical outcomes and enhancing the cost-efficiency of colonoscopy. The Company’s flagship product is the Pure-Vu® System, a U.S. FDA cleared medical device indicated to help facilitate the cleaning of a poorly prepared colon during the colonoscopy procedure. The device integrates with standard and slim colonoscopes to enable safe and rapid cleansing during the procedure while preserving established procedural workflow and techniques. The Pure-Vu® System has received CE mark approval in Europe. The Pure-Vu® System is currently being introduced on a pilot basis in the U.S. market, and the Company is planning to initiate a full commercial launch focused on the inpatient colonoscopy market in the U.S. and select international markets in 2019. Challenges with bowel preparation for inpatient colonoscopy represent a significant area of unmet need that directly affects clinical outcomes and increases the cost of care in a market segment that comprises approximately 1.5 million annual procedures in the U.S. and approximately 4 million annual procedures worldwide. Motus GI believes the Pure-Vu® System may improve outcomes and lower costs for hospitals by reducing the time to successful colonoscopy, minimizing delayed and aborted procedures, and improving the quality of an exam. In clinical studies to date, the Pure-Vu® System significantly increased the number of patients with an adequate cleansing level, according to the Boston Bowel Preparation Scale Score, a validated assessment instrument.
This press release contains certain forward-looking statements. Forward-looking statements are based on the Company’s current expectations and assumptions. The Private Securities Litigation Reform Act of 1995 provides a safe-harbor for forward-looking statements. These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential,” “predict,” “project,” “should,” “would” and similar expressions and the negatives of those terms, including without limitation, risks inherent in the development and commercialization of potential products, uncertainty in the timing and results of clinical trials or regulatory approvals, maintenance of intellectual property rights or other risks discussed in the Company’s Form 10-K filed on March 28, 2018, and its other filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.
View source version on businesswire.com:https://www.businesswire.com/news/home/20181001005261/en/
CONTACT: Investor and Media:
Jenene Thomas Communications, LLC
Jenene Thomas, 833-475-8247
KEYWORD: UNITED STATES NORTH AMERICA FLORIDA
INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY CLINICAL TRIALS MEDICAL DEVICES OTHER HEALTH GENERAL HEALTH
SOURCE: Motus GI Holdings, Inc.
Copyright Business Wire 2018.
PUB: 10/01/2018 08:05 AM/DISC: 10/01/2018 08:05 AM